CN102014936A - 间充质干细胞用于治疗遗传疾病和病症的用途 - Google Patents

间充质干细胞用于治疗遗传疾病和病症的用途 Download PDF

Info

Publication number
CN102014936A
CN102014936A CN2009801155331A CN200980115533A CN102014936A CN 102014936 A CN102014936 A CN 102014936A CN 2009801155331 A CN2009801155331 A CN 2009801155331A CN 200980115533 A CN200980115533 A CN 200980115533A CN 102014936 A CN102014936 A CN 102014936A
Authority
CN
China
Prior art keywords
gene
mesenchymal stem
stem cells
cells
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801155331A
Other languages
English (en)
Chinese (zh)
Inventor
蒂莫西·R·瓦尼
查尔斯·R·米尔斯
阿拉·丹尼尔科维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osiris Therapeutics Inc
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of CN102014936A publication Critical patent/CN102014936A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
CN2009801155331A 2008-03-05 2009-03-04 间充质干细胞用于治疗遗传疾病和病症的用途 Pending CN102014936A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/042,487 US20080286249A1 (en) 2006-01-12 2008-03-05 Use of mesenchymal stem cells for treating genetic diseases and disorders
US12/042,487 2008-03-05
PCT/US2009/001390 WO2009111030A1 (en) 2008-03-05 2009-03-04 Use of mesenchymal stem cells for treating genetic diseases and disorders

Publications (1)

Publication Number Publication Date
CN102014936A true CN102014936A (zh) 2011-04-13

Family

ID=40635808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801155331A Pending CN102014936A (zh) 2008-03-05 2009-03-04 间充质干细胞用于治疗遗传疾病和病症的用途

Country Status (10)

Country Link
US (8) US20080286249A1 (https=)
EP (1) EP2262513A1 (https=)
JP (1) JP6037597B2 (https=)
CN (1) CN102014936A (https=)
AU (1) AU2009220137A1 (https=)
BR (1) BRPI0909817A2 (https=)
CA (1) CA2717498A1 (https=)
MX (1) MX2010009767A (https=)
NZ (1) NZ587809A (https=)
WO (1) WO2009111030A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103183736A (zh) * 2011-12-27 2013-07-03 北京和信非凡生物技术有限公司 一种抗clcn7蛋白的单克隆抗体及其应用
CN104042606A (zh) * 2013-03-12 2014-09-17 国钦生物科技股份有限公司 苯酞化合物的应用
CN104726496A (zh) * 2015-03-27 2015-06-24 中国科学院生物物理研究所 携带人类成年早衰症基因突变的多能干细胞及制备方法
US11013716B2 (en) 2013-03-12 2021-05-25 Hawking Biological Technology Co., Ltd. Method for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, CXC chemokine receptor 4, and/or immune regulatory factor of stem cell

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
RU2539786C2 (ru) 2008-09-02 2015-01-27 Плуристем Лтд. Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
WO2011064733A1 (en) * 2009-11-27 2011-06-03 Stempeutics Research Pvt. Ltd. Methods of preparing mesenchymal stem cells, compositions and kit thereof
US20110142805A1 (en) * 2009-12-15 2011-06-16 Advanced Technologies And Regenerative Medicine, Llc Method of renal repair and regeneration and the treatment of diabetic nephropathy
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
KR101903339B1 (ko) * 2011-03-22 2018-10-01 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR20150065697A (ko) * 2012-09-04 2015-06-15 안트로제네시스 코포레이션 조직 생성 방법
WO2014087658A1 (en) * 2012-12-07 2014-06-12 Kuraray Co., Ltd. Method of cell fusion and fusion cells
EP3151847B1 (en) * 2014-06-04 2020-07-29 Cedars-Sinai Medical Center Human mesenchymal stem cells and pth for use in a method for non surgical repair of vertebral compression fractures
JP6890553B2 (ja) * 2015-06-11 2021-06-18 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 筋ジストロフィーキメラ細胞および筋ジストロフィーの処置方法
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN111406106A (zh) * 2017-11-28 2020-07-10 伊利诺伊大学理事会 多嵌合细胞以及移植疗法与免疫缺陷和遗传病症的治疗
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
WO2024183769A1 (en) * 2023-03-06 2024-09-12 Lingyi Biotech Co., Ltd. A truncated atp7b and the use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6962698B1 (en) * 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US7544509B2 (en) * 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
JPWO2003014336A1 (ja) * 2001-08-07 2004-11-25 麒麟麦酒株式会社 造血幹細胞の製造法
CA2460985C (en) * 2001-09-20 2016-01-05 Anticancer, Inc. Nestin-expressing hair follicle stem cells
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen
GB0304030D0 (en) * 2003-02-21 2003-03-26 King S College London Teeth
JP2007535486A (ja) * 2003-05-07 2007-12-06 ラ ホーヤ インスティチュート フォー モレキュラー メディシン 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法
US20050019801A1 (en) * 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
EP2399990B1 (en) * 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
US20050256077A1 (en) * 2004-03-30 2005-11-17 Henning Susan J Gastrointestinal stem cells and uses thereof
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103183736A (zh) * 2011-12-27 2013-07-03 北京和信非凡生物技术有限公司 一种抗clcn7蛋白的单克隆抗体及其应用
CN104042606A (zh) * 2013-03-12 2014-09-17 国钦生物科技股份有限公司 苯酞化合物的应用
CN104042606B (zh) * 2013-03-12 2017-05-24 国钦生物科技股份有限公司 苯酞化合物的应用
US11013716B2 (en) 2013-03-12 2021-05-25 Hawking Biological Technology Co., Ltd. Method for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, CXC chemokine receptor 4, and/or immune regulatory factor of stem cell
CN104726496A (zh) * 2015-03-27 2015-06-24 中国科学院生物物理研究所 携带人类成年早衰症基因突变的多能干细胞及制备方法
CN104726496B (zh) * 2015-03-27 2017-07-07 中国科学院生物物理研究所 携带人类成年早衰症基因突变的多能干细胞及制备方法

Also Published As

Publication number Publication date
US20140030235A1 (en) 2014-01-30
EP2262513A1 (en) 2010-12-22
US20100330052A1 (en) 2010-12-30
NZ587809A (en) 2012-08-31
US20130121975A1 (en) 2013-05-16
WO2009111030A1 (en) 2009-09-11
BRPI0909817A2 (pt) 2017-06-13
US20100291047A1 (en) 2010-11-18
US20120263687A1 (en) 2012-10-18
AU2009220137A1 (en) 2009-09-11
JP6037597B2 (ja) 2016-12-07
US20080286249A1 (en) 2008-11-20
CA2717498A1 (en) 2009-09-11
US20140322180A1 (en) 2014-10-30
JP2011514901A (ja) 2011-05-12
US20110177045A1 (en) 2011-07-21
MX2010009767A (es) 2010-09-28

Similar Documents

Publication Publication Date Title
JP6037597B2 (ja) 遺伝子疾患および障害を治療するための間葉系幹細胞の使用
AU2013205951B2 (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
Lee et al. Hematopoietic stem cells and their roles in tissue regeneration
Mahla Stem cells applications in regenerative medicine and disease therapeutics
Grove et al. Plasticity of bone marrow–derived stem cells
Young et al. Treating Parkinson disease with adult stem cells
Mohammedsaleh The use of patient-specific stem cells in different autoimmune diseases
Kizilay et al. Effect of systemic application of bone marrow-derived mesenchymal stem cells on healing of peripheral nerve injury in an experimental sciatic nerve injury model
Aejaz et al. Stem cell therapy—Present status
Dilip Kumar et al. Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine
Park et al. [Retracted] Regenerative Medicine for Neurological Disorders
Payne et al. The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis
Köse et al. Stem cell applications in lysosomal storage disorders: progress and ongoing challenges
AU2015201881A1 (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
Xiong et al. Microdystrophin delivery in dystrophin-deficient (mdx) mice by genetically-corrected syngeneic MSCs transplantation
Tominari et al. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy
Ripoll Adult stem cell therapy in the twitcher mouse model of Krabbe's disease utilizing mesenchymal lineage stem cells
Takenaka-Ninagawa et al. Muscular Dystrophy and Rehabilitation Interventions with Regenerative Treatment
Eve The continued promise of stem cell therapy in regenerative medicine
KR20230140802A (ko) 줄기세포의 기능 강화용 조성물 및 이의 용도
North et al. Stem cell therapies for the treatment of spinal cord injuries: current progress in basic science and clinical research
an Experimental Potently Immunosuppressive 5-Fluorouracil
Taupin Stem Cells and Regenerative Medicine: Volume III: Pharmacology and Therapy
Alexanian Mesenchymal Stem Cells in CNS Regeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20110413